Of the 12 short vaccine group HCWs with a confirmed breakthrough infection 92% (11/12) had an increase in anti-N and 83% (10/12) in anti-S1 antibodies, and 83% (10/12) had at least a 4x-increase in Omicron BA.5-specific neutralizing titers. This evidence concerns the gene PSMD1 and infection.